Nachrichten zur Pfizer Aktie

Pfizer Hold

HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Pfizer mit einem Kursziel von 27 US-Dollar auf "Hold"…

Berenberg belässt Pfizer auf Hold - Ziel 27 Dollar

HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Pfizer mit einem Kursziel von 27 US-Dollar auf "Hold"…

GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac

mRNA specialist CureVac, which struggled to compete with the likes of Pfizer, Moderna and BioNTech, said it will focus on…

Global Allergy Therapeutics Market Size To Exceed USD 42.5 Billion By 2033 | CAGR Of 6.29%

The Global Allergy Therapeutics Market Size was Valued at USD 23.1 Billion in 2023 and the Worldwide Allergy Therapeutics Market…

Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?

Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and…

Pharma Giants Claim Partial Wins in UK Case over Covid Vaccine Profits

Moderna Inc. scored a partial victory in its attempt to claim a share of billions of dollars in profits made…

1 Underwhelming Stat That May Have You Thinking Twice About Buying Pfizers Stock

Pfizers valuation looks attractive, but that doesnt mean the stock is a lock to outperform the broader market.…

1 Underwhelming Stat That May Have You Thinking Twice About Buying Pfizers Stock @themotleyfool #stocks $PFE

Pfizers valuation looks attractive, but that doesnt mean the stock is a lock to outperform the broader market.…

Pfizer: It Could Be A Bargain

…

Pfizer And Moderna Vaccines Not Linked To Birth Defects, Study Finds

The findings add to research showing vaccination during pregnancy is safe and effective amid growing evidence of severe risks from…

Pfizer Aktie: EU-Zulassung für Omikron-Impfstoff

Pfizer und BioNTech haben einen bedeutenden Meilenstein erreicht: Die Europäische Arzneimittelagentur hat ihrer angepassten monovalenten COVID-19-Vakzine für den Omikron-Stamm JN.1…

Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline

CNBC spoke with 11 current and former Pfizer employees, who asked to remain anonymous, about Pfizers dizzying climb, rapid decline…

Pfizer (PFE), BioNTechs Updated COVID-19 Jab Gets CHMP Nod

Pfizer (PFE) and BioNTechs Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Uses positive opinion recommending…

BioNTech Aktie: Neuer Impfstoff Empfehlung Erhalten

Pfizer und BioNTech haben kürzlich eine wichtige Empfehlung für ihren neuesten COVID-19-Impfstoff von der europäischen Arzneimittelbehörde erhalten. Dieser auf Omikron…

Moderna: Erhöhtes Risiko für RSV-Schätzungen - Aktienanalyse

New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Evercore ISI: Cory Kasimov, Analyst von Evercore ISI, bestätigt sein Rating und Kursziel für die…

GNW-Adhoc: Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron JN.1 angepassten COVID-19-Impfstoff in der Europäischen Union

^* Der aktualisierte COVID-19-Impfstoff ist auf die Omikron JN.1-Sublinie von SARS-CoV-2 zugeschnitten und wird für Personen ab…

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union

NEW YORK and MAINZ, Germany, June 27, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”)…

GSK and Moderna slide on RSV vaccine CDC updates

GSK PLC (LSE:GSK, NYSE:GSK) shares fell 6% after US authorities recommended restrictions on doses of any respiratory syncytial virus (RSV) vaccine.…

CDC advisors narrow age recommendation for RSV shots in U.S.

Last year, GSK and Pfizer went head-to-head with rival RSV shots for all adults aged 60 and over, who could…

Moderna says its RSV shot is 50% effective after 18 months

In their clinical trials, GSKs RSV vaccine Arexvy was 78% effective in preventing severe RSV over a second year and…

Is Pfizers Pain Sarepta Therapeutics Gain? Dont Bet on It.

One companys negative results can increase scrutiny of anothers work.…

Pfizers Working on the Next Wegovy, but Can It Beat Novo Nordisk?

This is a matchup that the latecomer might not be able to win.…

Pfizer CEO reveals new weight loss drug mechanism in works

…

Global Contraceptive Drugs Market Size To Worth USD 40.08 Billion By 2033 | CAGR Of 8.02%

The Global Contraceptive Drugs Market Size was Valued at USD 18.53 Billion in 2023 and the Worldwide Contraceptive Drugs Market…

Pfizer (PFE) Stock Sinks As Market Gains: Heres Why

Pfizer (PFE) closed at $27.99 in the latest trading session, marking a -1.3% move from the prior day.…

Global Parkinson’s Disease Treatment Market Size To Worth USD 9.14 Billion By 2033 | CAGR Of 6.41%

The Global Parkinsons Disease Treatment Market Size was Valued at USD 4.91 Billion in 2023 and the Worldwide Parkinsons Disease…

UK Government Snubs GSK in Favor of Pfizer’s Rival RSV Shot

GSK Plc has lost out to Pfizer Inc. on a contract to supply millions of doses of its blockbuster RSV…

Pfizer: Seriously Undervalued At Peak Pessimism

…

Investing for the Next 12 Months? Buy These

If investors expect interest rates to hold until next year, they should consider dividend-yielding stocks like Altria (NYSE: MO), Bristol…

AKTIONÄR-Alt-Empfehlung Sarepta: "Homerun" – Aktie explodiert – Pfizer schaut in die Röhre

Die Biotech-Gesellschaft Sarepta Therapeutics fokussiert sich seit vielen Jahren auf die Entwicklung von gentherapeutischen Ansätzen zur Behandlung von Duchenne Muskeldystrophie…

The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly

Pfizer, Johnson & Johnson and Eli Lilly are part of the Zacks top Analyst Blog.…

Global Anal Fissure Treatment Market Size To Exceed USD 1986.1 Million By 2033 | CAGR Of 5.51%

The Global Anal Fissure Treatment Market Size was Valued at USD 1161.3 Million in 2023 and the Worldwide Anal Fissure…

Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies in 2024

Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking…

Pfizer sued in Kansas over COVID-19 vaccine

…

Impfstoff: US-Bundesstaat verklagt Pfizer

Verschwiegene Risiken, falsche Behauptungen zur Sicherheit und Unterdrückung kritischer Stimmen auf Social Media - die Klage, die der US-Bundesstaat Kansas…

Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb @themotleyfool #stocks $PFE $BMY

These two pharma stocks are beloved by income investors.…

Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb

…

Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb

These two pharma stocks are beloved by income investors.…

Pfizer Stock: The Reversal Should Keep Going

…

Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit By Reuters

Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit…

Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%

The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…

Pharma Stock Roundup: FDA Panel Endorses LLYs Donanemab, PFEs DMD Therapy Study Fails

An FDA panel endorses Eli Lillys (LLY) Alzheimers disease drug, donanemab. Pfizers (PFE) DMD study on investigational gene therapy fails.…

Sarepta Therapeutics gains as Pfizer failure removes overhang By Investing.com

Sarepta Therapeutics gains as Pfizer failure removes overhang…

Pfizer: Studienrückschlag dürfte die Aktie kurzfristig weiter ausbremsen - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Pfizer-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Pfizer Inc. (ISIN: US7170811035,…

Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon

…

Pfizer: Rückschlag!

Der amerikanische Pharma-Riese muss einen weiteren herben Dämpfer hinnehmen. In einer klinischen Phase-3-Studie konnte Pfizer mit einer potenziellen Gentherapie zur…

Pfizer: Rückschlag!

Der amerikanische Pharma-Riese muss einen weiteren herben Dämpfer hinnehmen. In einer klinischen Phase-3-Studie konnte Pfizer mit einer potenziellen Gentherapie zur…

Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal

Pfizers (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with…

Global Prostate Health Market Size To Worth USD 78.03 Billion By 2033 | CAGR Of 9.12%

The Global Prostate Health Market Size was Valued at USD 32.6 Billion in 2023 and the Worldwide Prostate Health Market…

Pfizer: Deal mit Flagship Pioneering - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Pfizer-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Pfizer Inc. (ISIN: US7170811035,…